A Study to Evaluate the Relationship Between Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Cancer.
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2016
At a glance
- Drugs Ramucirumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly; ImClone Systems
- 01 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Apr 2014 Planned End Date changed from 1 Mar 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 03 Mar 2014 Planned End Date changed from 1 Jan 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov.